TP53 mutations in human cancers: origins, consequences, and clinical use.

Cited by (1,002)

Items 501–600 of 1,002

1. Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression
   Riyue Feng, Yin Yin, Yuge Wei, Yang Li, Lei Li, Rui Zhu, Yu Xiao, Yuhao Liu, Yahui Zhao, Zhihua Liu · 2023 · Cancer Letters
2. Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
   Tancredi Didier Bazan Russo, Clarissa Mujacic, Emilia Di Giovanni, Maria Concetta Vitale, Carla Ferrante Bannera, Ugo Randazzo, Silvia Contino, Marco Bono, Valerio Gristina, Antonio Galvano et al. · 2024 · Cancer Gene Therapy
3. A rare DNA contact mutation in cancer confers p53 gain‐of‐function and tumor cell survival via TNFAIP8 induction
   Jessica Monteith, Hestia S. Mellert, Morgan A. Sammons, Laudita A. Kuswanto, Stephen Matthew Sykes, Lois Resnick‐Silverman, James J. Manfredi, Shelley L. Berger, Steven B. McMahon · 2016 · Molecular Oncology
4. Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4
   Homa Rahnamoun, Juyeong Hong, Zhengxi Sun, Ji Hoon Lee, Hanbin Lu, Shannon M. Lauberth · 2018 · Journal of Biological Chemistry
5. Enzymatic Litmus Test for Selective Colorimetric Detection of C–C Single Nucleotide Polymorphisms
   Michael G. Wolfe, M. Monsur Ali, John D. Brennan · 2019 · Analytical Chemistry
6. Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress
   Cheng-Jung Ho, Ru‐Wei Lin, Weihua Zhu, Tsung‐Kai Wen, Chieh‐Ju Hu, Yi-Lin Lee, Ta-I Hung, Chihuei Wang · 2019 · Cell Death Discovery
7. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
   Beatrice Gini, Nicholas J. Thomas, Collin Michael Blakely · 2020 · Journal of Thoracic Disease
8. Interpretation of p16, p53 and mismatch repair protein immunohistochemistry in gynaecological neoplasia
   Richard Wing-Cheuk Wong, Andrea Palicelli, Lien N. Hoang, Naveena Singh · 2020 · Diagnostic histopathology
9. Lipid Regulatory Proteins as Potential Therapeutic Targets for Ovarian Cancer in Obese Women
   Jing Yang, Mary Sharon Stack · 2020 · Cancers
10. Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer
    Yari Ciani, Tarcisio Fedrizzi, Davide Prandi, Francesca Lorenzin, Alessio Locallo, Paola Gasperini, Gian Marco Franceschini, Matteo Benelli, Olivier Elemento, Luca L. Fava et al. · 2021 · Cell Systems
11. Inhibition of p53 protein aggregation as a cancer treatment strategy
    Kalvin Kwan, Omar Castro-Sandoval, Christian Gaiddon, Tim Storr · 2022 · Current Opinion in Chemical Biology
12. Targeting mutant p53 stabilization for cancer therapy
    Jiajian Wang, Wenjun Liu, Lanqing Zhang, Jihong Zhang · 2023 · Frontiers in Pharmacology
13. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer
    Jiahui Liang, Xin Wang, Jing Hua Yang, Peng Sun, Jingjing Sun, Shengrong Cheng, Jincheng Liu, Zhiyao Ren, Min Ren · 2023 · Frontiers in Immunology
14. Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer
    Ke Chen, Kongming Wu, Michael Gormley, Adam Ertel, Jing Wang, Wei Zhang, Jie Zhou, Gabriele DiSante, Zhiping Li, Hallgeir Rui et al. · 2013 · Oncotarget
15. Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations
    Sungjin Park, Jinhyuk Lee, Yon Hui Kim, Jaheun Park, Jung‐Woog Shin, Seungyoon Nam · 2016 · Scientific Reports
16. A Study of TP53 RNA Splicing Illustrates Pitfalls of RNA-seq Methodology
    Sunali Y. Mehta, Peter Tsai, Annette Lasham, Hamish G. Campbell, Roger R. Reddel, Antony W. Braithwaite, Cristin Gregor Print · 2016 · Cancer Research
17. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis
    Cielito C. Reyes‐Gibby, Stephanie C. Melkonian, Jian Wang, Robert K. Yu, Samuel A. Shelburne, Charles S. Lu, G. Brandon Gunn, Mark Steven Chambers, Ehab Y. Hanna, Sai‐Ching J. Yeung et al. · 2017 · PLoS ONE
18. Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach
    Vivían D’Afonseca, Ariel Domingo Arencibia, Alex Echeverría-Vega, Leslie C. Cerpa, Juan Pablo Cayún, Nelson Varela, Marcela Salazar, Luis A. Quiñones · 2020 · Cancer Informatics
19. Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis
    Songtao Li, Xiuyun He, Linjie Ruan, Ting Ye, Yulong Wen, Zhihua Song, Siying Hu, Yu Chen, Bo Peng, Shijie Li · 2021 · Frontiers in Oncology
20. Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
    Mehregan Babamohamadi, Esmaeil Babaei, Burhan Ahmed Salih, Mahshid Babamohammadi, Hewa Jalal Azeez, Goran Qader Othman · 2022 · Frontiers in Molecular Biosciences
21. Antioxidant and chemotherapeutic efficacies of seaweed‐derived phlorotannins in cancer treatment: A review regarding novel anticancer drugs
    Biswajita Pradhan, Jang‐Seu Ki · 2023 · Phytotherapy Research
22. Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas
    Monica Gostissa, Julia M. Bianco, Daniel J. Malkin, Jeffery Lorne Kutok, Scott J. Rodig, Herbert C. Morse, Craig H. Bassing, Frederick W. Alt · 2013 · Proceedings of the National Academy of Sciences
23. C2-Streptavidin Mediates the Delivery of Biotin-Conjugated Tumor Suppressor Protein P53 into Tumor Cells
    Jörg Fahrer, Brigitte Schweitzer, Katja Fiedler, Torben Langer, Peter Gierschik, Holger Barth · 2013 · Bioconjugate Chemistry
24. Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies
    Zhengdong Yang, Xinyang Wang, Huiying Zhou, Minghan Jiang, Jinghui Wang, Bowen Sui · 2024 · Cancer Management and Research
25. Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
    Timothy G. Whitsett, Amanda L. Richer, Jacqueline M. Friel, Vashti M. Carson, Landon J. Inge · 2015 · Pharmacogenomics and Personalized Medicine
26. FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3
    Martina Rupp, Judith Hagenbuchner, Bettina Rass, Heidi Fiegl, Ursula Kiechl‐Kohlendorfer, Petra Obexer, Michael J. Ausserlechner · 2017 · Oncogene
27. Mouse Homolog of the Human TP53 R337H Mutation Reveals Its Role in Tumorigenesis
    Jihoon Park, Jie Li, Matthew F. Starost, Chengyu Liu, Jie Zhuang, Jichun Chen, Maria Isabel Achatz, Ju‐Gyeong Kang, Pingyuan Wang, Sharon A. Savage et al. · 2018 · Cancer Research
28. RRAD, IL4I1, CDKN1A, and SERPINE1 genes are potentially co-regulated by NF-κB and p53 transcription factors in cells exposed to high doses of ionizing radiation
    Katarzyna Szołtysek, Patryk Janus, Gracjana Zając, Tomasz Stokowy, Anna Walaszczyk, Wiesława Widłak, Bartosz Wojtaś, Bartłomiej Gielniewski, Simon Cockell, Neil D. Perkins et al. · 2018 · BMC Genomics
29. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
    Víctor Cervera-Carrascón, Riikka Havunen, Akseli Hemminki · 2019 · Expert Opinion on Biological Therapy
30. Controlling Structural Bias in Intrinsically Disordered Proteins Using Solution Space Scanning
    Alex S. Holehouse, Shahar Sukenik · 2020 · Journal of Chemical Theory and Computation
31. Human induced pluripotent stem cells and CRISPR/Cas-mediated targeted genome editing: Platforms to tackle sensorineural hearing loss
    Miodrag Stojković, Dongjun Han, Minjin Jeong, Petra Stojković, Konstantina M. Stanković · 2021 · Stem Cells
32. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms
    Qihang Yuan, Jie Ren, Zhizhou Wang, Ji Li, Dawei Deng, Dong Shang · 2021 · Frontiers in Genetics
33. Reduced ER–mitochondria connectivity promotes neuroblastoma multidrug resistance
    Jorida Çoku, David M. Booth, Jan Skoda, Madison C. Pedrotty, Jennifer Vogel, Kangning Liu, Annette T. Vu, Erica L. Carpenter, Jamie C. Ye, Michelle A. Chen et al. · 2022 · The EMBO Journal
34. The Long and the Short of It: NEAT1 and Cancer Cell Metabolism
    Nadine E. Smith, Phaedra Spencer-Merris, Archa H. Fox, Janni Petersen, Michael Michael · 2022 · Cancers
35. Identification of FDA‐approved Drugs that Computationally Bind to MDM2
    Wayne A. Warner, Ricardo Sanchez, Alex Dawoodian, Esther Li, Jamil Antonio Momand · 2012 · Chemical Biology & Drug Design
36. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies
    Rami M. Elshazli, Eman Ali Toraih, Abdelaziz Elgaml, Emad H. Kandil, Manal Said Fawzy · 2020 · Gene
37. In Vitro Prostate Cancer Treatment via CRISPR‐Cas9 Gene Editing Facilitated by Polyethyleneimine‐Derived Graphene Quantum Dots
    Bong Han Lee, Klara Gries, Alina R. Valimukhametova, Ryan Lee McKinney, Roberto González-Rodríguez, Ugur Can Topkiran, Jeffery L. Coffer, Giridhar Rao Akkaraju, Anton V. Naumov · 2023 · Advanced Functional Materials
38. P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation
    Kostas A. Papavassiliou, Amalia A. Sofianidi, Vassiliki A. Gogou, Nektarios Anagnostopoulos, Athanasios G. Papavassiliou · 2024 · International Journal of Molecular Sciences
39. PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53
    Thomas Grellety, Audrey Laroche‐Clary, Vanessa Chaire, Pauline Lagarde, Frédéric Chibon, Agnès Neuville, Antoîne Italiano · 2015 · BMC Cancer
40. Over-Expression of Alpha-Enolase as a Prognostic Biomarker in Patients with Pancreatic Cancer
    Lichao Sun, Chunguang Guo, Jianzhong Cao, Joseph Burnett, Zhihua Yang, Yuliang Ran, Duxin Sun · 2017 · International Journal of Medical Sciences
41. Mutational interactions define novel cancer subgroups
    Jack Kuipers, Thomas Thurnherr, Giusi Moffa, Polina Suter, Jonas Behr, Ryan Goosen, Gerhard Christofori, Niko Beerenwinkel · 2018 · Nature Communications
42. A Circular RNA from the MDM2 Locus Controls Cell Cycle Progression by Suppressing p53 Levels
    Ritu Chaudhary, Bruna Rodrigues Muys, Ioannis Grammatikakis, Supriyo De, Kotb Abdelmohsen, Xiao Ling Li, Yuelin Jack Zhu, Swapna Vidhur Daulatabad, Dimitrios Tsitsipatis, Paul S. Meltzer et al. · 2020 · Molecular and Cellular Biology
43. Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression
    Xiangui Meng, Zhiyong Xiong, Wen Xiao, Changfei Yuan, Cheng Wang, Yu Huang, Junwei Tong, Jian Shi, Zhixian Chen, Chenchen Liu et al. · 2020 · Annals of Translational Medicine
44. Regulation of DNA Damage Response and Homologous Recombination Repair by microRNA in Human Cells Exposed to Ionizing Radiation
    Magdalena Szatkowska, Renata Krupa · 2020 · Cancers
45. Sensitive biosensor for p53 DNA sequence based on the photothermal effect of gold nanoparticles and the signal amplification of locked nucleic acid functionalized DNA walkers using a thermometer as readout
    Yingzhou Tao, Weijia Wang, Caili Fu, Fang Luo, Longhua Guo, Bin Qiu, Zhenyu Lin · 2020 · Talanta
46. Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
    Aya Saleh, Ruth Perets · 2021 · Cancers
47. Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer–Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis
    Paula Rofes, Sara González, Matilde Navarro, José Marcos Moreno-Cabrera, Ares Solanes, Esther Darder, Estela Carrasco, Silvia L. Iglesias, Mónica Salinas, Carolina Gómez et al. · 2021 · Journal of Molecular Diagnostics
48. Anti-cancer properties of Caulerpa racemosa by altering expression of Bcl-2, BAX, cleaved caspase 3 and apoptosis in HeLa cancer cell culture
    Happy Kurnia Permatasari, Defny S. Wewengkang, Nur Iedha Tertiana, Farida Zharfani Muslim, Muhammad Fakhrur Rajih Hi Yusuf, Shintya Octaviana Baliulina, Vanessa Pradna Adyana Daud, Aurielle Annalicia Setiawan, Fahrul Nurkolis · 2022 · Frontiers in Oncology
49. BRCA1 and p53 regulate critical prostate cancer pathways
    P. De Luca, CP Moiola, F. Zalazar, K. Gardner, E. Vazquez, A. De Siervi · 2013 · Prostate Cancer and Prostatic Diseases
50. Convolvulus galaticus , Crocus antalyensis , and Lilium candidum Extracts Show Their Antitumor Activity Through Induction of p53-Mediated Apoptosis on Human Breast Cancer Cell Line MCF-7 Cells
    Onur Tokgün, Hakan Akça, Ramazan Mammadov, Candan Aykurt, Gökhan Deniz · 2012 · Journal of Medicinal Food
51. Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi
    Oriol Yélamos, Emily A. Merkel, Lauren Meldi Sholl, Bin Zhang, Sapna M. Amin, Christina Y. Lee, Gerta E. Guitart, Jingyi Yang, Alexander T. Wenzel, Christopher G. Bunick et al. · 2016 · Journal of Investigative Dermatology
52. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review
    Francesco Jacopo Romano, Sabrina Rossetti, Vincenza Conteduca, Giuseppe Schepisi, Carla Cavaliere, Rossella Di Franco, Elvira La Mantia, Luigi Castaldo, Flavia Nocerino, Gianluca Ametrano et al. · 2016 · Oncotarget
53. Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer
    Martin L. Read, Jim C. Fong, Bhavin Modasia, Anne L. Fletcher, Waraporn Imruetaicharoenchoke, R J Thompson, Hannah R. Nieto, John J. Reynolds, Andrea Bacon, Ujjal K. Mallick et al. · 2017 · Oncogene
54. Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition
    Prashanth Jyothi Prabakaran, Amal M. Javaid, Adam D. Swick, Lauryn R. Werner, Kwangok P. Nickel, Emmanuel Sampene, Rong Hu, Irene M. Ong, Justine Y. Bruce, Gregory K. Hartig et al. · 2017 · Clinical Cancer Research
55. Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers
    Chen Katz, Ana María Low-Calle, Joshua H. Choe, Oleg Laptenko, David Tong, Jazmine-Saskya N. Joseph-Chowdhury, Francesca Garofalo, Yan Yu Zhu, Assaf Friedler, Carol L. Prives · 2018 · Genes & Development
56. KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion
    Hisataka Sabe · 2023 · Cell Communication and Signaling
57. Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
    Cristina Díaz del Arco, María Jesús Fernández‐Aceñero, Luis M Ortega · 2024 · International Journal of Molecular Sciences
58. Whole-Genome Sequencing Analysis Identifies a Distinctive Mutational Spectrum in an Arsenic-Related Lung Tumor
    Victor D. Martínez, Kelsie L. Thu, Emily A. Vucic, Roland Hubaux, Marta Adonis, Lionel Gil, Calum E. MacAulay, Stephen C. Lam, Wan L. Lam · 2013 · Journal of Thoracic Oncology
59. Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish
    David Philip Lane, Arumugam Madhumalar, Alison Lee, Boon-Hui Tay, Chandra Shekhar Verma, Sydney Brenner, Byrappa Venkatesh · 2011 · Cell Cycle
60. Interaction between the Cockayne syndrome B and p53 proteins: implications for aging
    Mattia Frontini, Luca Proietti‐De‐Santis · 2012 · Aging
61. Nutlin‐3a selects for cells harbouring TP 53 mutations
    Jill E. Kucab, Monica C. Hollstein, Volker Manfred Arlt, David H. Phillips · 2016 · International Journal of Cancer
62. Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties
    Ankush Garg, Jagadish Prasad Hazra, Malay Kumar Sannigrahi, Sabyasachi Rakshit, Sharmistha Sinha · 2019 · Biophysical Journal
63. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity
    Tamara Isermann, Özge Cicek Sener, Adrian Stender, Luisa Klemke, Nadine Winkler, Albrecht Neeße, Jinyu Li, Florian Wegwitz, Ute Martha Moll, Ramona Schulz‐Heddergott · 2021 · Nature Communications
64. p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer
    Eunhyang Park, Hyun Ho Han, Sung-Eun Choi, Hyunjin Park, Ha Young Woo, Mi Jang, Hyo Sup Shim, Sohyun Hwang, Haeyoun Kang, Nam-Hoon Cho · 2022 · Diagnostics
65. The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding
    Ana Sara Gomes, Filipa Trovão, B. Pinheiro, Filipe Freire, Sara Gomes, Carla Oliveira, Lucı́lia Domingues, Maria João Romão, Lucı́lia Saraiva, Ana Luı́sa Carvalho · 2018 · International Journal of Molecular Sciences
66. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death
    Conradt, Laura, Henrich, Annika, Wirth, Matthias, Reichert, Maximilian, Lesina, Marina, Algül, Hana, Schmid, Roland M., Krämer, Oliver H., Saur, Dieter, Schneider, Günter · 2013 · International Journal of Cancer
67. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis
    Mostafa A. Abdel-Maksoud · 2024 · American Journal of Translational Research
68. Mutant p53 – Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival
    Evguenia M. Alexandrova, Natalia D. Marchenko · 2015 · Frontiers in Endocrinology
69. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer
    Katherine Andrea Palacio Rúa, L.F. Isaza-Jiménez, Enoc Ahumada Rodríguez, Hamilton Ceballos, Carlos Mario Muñetón Peña · 2014 · Revista de Gastroenterología de México (English Edition)
70. Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors
    Peixin Dong, Kei Ihira, Junichi Hamada, Hidemichi Watari, Takahiro Yamada, Masayoshi Hosaka, Sharon J. B. Hanley, 正尊 工藤, Noriaki Sakuragi · 2015 · Oncotarget
71. Efficient generation of P53 biallelic knockout Diannan miniature pigs via TALENs and somatic cell nuclear transfer
    Youfeng Shen, Kaixiang Xu, Zaimei Yuan, Jianxiong Guo, Heng Zhao, Xuezeng Zhang, Lu Zhao, Yubo Qing, Honghui Li, Weirong Pan et al. · 2017 · Journal of Translational Medicine
72. Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus‑positive cirrhosis
    Qifeng Chen, Jin‐Guo Xia, Wang Li, Lujun Shen, Tao Huang, Peihong Wu · 2018 · Molecular Medicine Reports
73. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
    Christos Petridis, Iteeka Arora, Vandna Shah, Anargyros Megalios, Charlotte Louise Moss, Anca Mera, Angela Clifford, Cheryl Gillett, Sarah E. Pinder, Ian P.M. Tomlinson et al. · 2019 · Breast Cancer Research
74. Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa
    Martin Bartas, Václav Brázda, Jiří Červeň, Petr Pečínka · 2019 · International Journal of Molecular Sciences
75. Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors
    Yasutaka Sakurai, Masaaki Ichinoe, Kazuki Yoshida, Yuka Nakazato, Shoji Saito, Masashi Satoh, Norihiro Nakada, Itaru Sanoyama, Atsuko Umezawa, Yoshiko Numata et al. · 2020 · Cancer Letters
76. Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin
    Lubna Therachiyil, Javeria Haroon, Fairooz Sahir, Kodappully Sivaraman Siveen, Shahab Uddin M.S., Michał Kuliński, Joerg Buddenkotte, Martin S. Steinhoff, Roopesh Krishnankutty · 2020 · Frontiers in Oncology
77. TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients
    Yasir Hameed, Samina Ejaz · 2020 · Journal of Cancer Research and Therapeutics
78. Integrated systems biology approach using gene network analysis to identify the important pathways and new potential drug targets for Neuroblastoma
    Gayathri Ashok, Sravan Kumar Miryala, Anand Anbarasu, Sudha Ramaiah · 2021 · Gene Reports
79. PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response
    Zdeněk Andrysík, Kelly D. Sullivan, Jeffrey S. Kieft, Joaquin Maximiliano Espinosa · 2022 · Nature Communications
80. p53 and its mutants on the slippery road from stemness to carcinogenesis
    Alina Molchadsky, Varda Rotter · 2017 · Carcinogenesis
81. MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress
    Elizabeth I. Spehalski, Kayla Capper, Cheryl Jacobs Smith, Mary J. Morgan, Maria Dinkelmann, Jeffrey M. Buis, JoAnn Sekiguchi, David O. Ferguson · 2017 · Cancer Research
82. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
    Mianen Sun, Pan Tong, Wen Kong, Baijun Dong, Yiran Huang, In Young Park, Lijun Zhou, Xian-De Liu, Zhiyong Ding, Xuesong Zhang et al. · 2017 · Cancer Research
83. An Overview of Molecular Cancer Pathogenesis, Prognosis, and Diagnosis
    John Michael Cullen, Matthew Breen · 2016 · Wiley eBooks
84. Expression Characteristics and Significant Prognostic Values of PGK1 in Breast Cancer
    Yanping Li, Shanshan Wang, Xiaoyuan Zhang, Rui Yang, Xiaonan Wei, Ruirong Yan, Yaru Jiang, Wenzhi Shen · 2021 · Frontiers in Molecular Biosciences
85. Accurate TCR-pMHC interaction prediction using a BERT-based transfer learning method
    Jiawei Zhang, Wang Ma, Hui Jun Yao · 2023 · Briefings in Bioinformatics
86. Knocking down of p53 triggers apoptosis and autophagy, concomitantly with inhibition of migration on SSC-4 oral squamous carcinoma cells
    Alexandra Iulia Irimie, Cornelia Braicu, Valentina Pileczki, Bobe Petrushev, Olga Şoriţău, Radu Septimiu Câmpian, Ioana Berindan‐Neagoe · 2016 · Molecular and Cellular Biochemistry
87. The Role of p53/p21/p16 in DNA-Damage Signaling and DNA Repair
    Yavuz Kulaberoglu, Ramazan Gündoğdu, Alexander Hergovich · 2016 · Elsevier eBooks
88. Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer
    Yun Feng, Hongliang Liu, Bensong Duan, Zhensheng Liu, James L. Abbruzzese, Kyle M. Walsh, Xuefeng Zhang, Qingyi Wei · 2019 · Carcinogenesis
89. Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint
    Emilija Manojlović-Gačić, Jens Bollerslev, Olivera Casar‐Borota · 2019 · Neuropathology and Applied Neurobiology
90. Synthesis and Evaluation of Artemisinin-Based Hybrid and Dimer Derivatives as Antimelanoma Agents
    Lorenzo Botta, Silvia Filippi, Bruno Mattia Bizzarri, Claudio Zippilli, Roberta Meschini, Rebecca Pogni, Maria Camilla Baratto, Luciano Villanova, Raffaele Saladino · 2019 · ACS Omega
91. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
    Linsong Tang, Ronggao Chen, Xiao Xu · 2020 · Cancer Letters
92. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas
    Christoph Arolt, Moritz Friedo Meyer, Vanessa Rüsseler, Lisa Nachtsheim, Nora Wuerdemann, Thomas Dreyer, Stefan Gattenlöhner, Claus Wittekindt, Reinhard Buettner, Alexander Quaas et al. · 2020 · Cancer Immunology Immunotherapy
93. A Reliable BioFET Immunosensor for Detection of p53 Tumour Suppressor in Physiological-Like Environment
    Chiara Baldacchini, Antonino Francesco Montanarella, Luca Nunzio Francioso, Maria Assunta Signore, Salvatore Cannistraro, Anna Rita Bizzarri · 2020 · Sensors
94. DNA damage in cancer development: special implications in viral oncogenesis.
    Meghri Katerji, Penelope J. Duerksen-Hughes · 2021 · PubMed Central
95. Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy
    Sara Jaber, Marine Warnier, Christopher Leers, Mathieu Vernier, Delphine Goehrig, Jean‐Jacques Médard, David Vindrieux, Dorian V. Ziegler, David Bernard · 2023 · Molecular Biomedicine
96. Preferential binding of p53 tumor suppressor to p21 promoter sites that contain inverted repeats capable of forming cruciform structure
    Jan Coufal, Eva B. Jagelská, Jack C. C. Liao, Václav Brázda · 2013 · Biochemical and Biophysical Research Communications
97. Four Promoters of IRF5 Respond Distinctly to Stimuli and are Affected by Autoimmune-Risk Polymorphisms
    Daniel N. Clark, R. Daniel Read, Vera M. Todd, Stephen C. Petersen, Lissenya B. Argueta, Lance A. Stutz, Rodney E. Till, Sean M. Bergsten, Brandon S. Robinson, Douglas G. Baumann et al. · 2013 · Frontiers in Immunology
98. Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old.
    Ting Ye, Yunjian Pan, Rui Wang, Haichuan Hu, Yang Zhang, Hang Li, Lei Wang, Yihua Sun, Haiquan Chen · 2014 · PubMed Central
99. Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
    Stephanie Kaypee, Smitha Asoka Sahadevan, Shilpa Patil, Piya Ghosh, Neeladri Sekhar Roy, Siddhartha Roy, Tapas Kumar Kundu · 2018 · iScience
100. Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases
     Han Hong Lee, Su Young Kim, Eun Sun Jung, Jinseon Yoo, Tae‐Min Kim · 2018 · Gastric Cancer